Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Dermatology | Family Medicine | Nursing | Pharmacy | Rheumatology | Journal

Back to Journal Articles

Leflunomide Considered Safe, Effective for Psoriatic Arthritis

Last Updated: October 12, 2012.

 

Improvements seen in joint scores, pain, fatigue, dactylitis, and skin disease

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Leflunomide is effective for the treatment of patients with psoriatic arthritis in daily clinical practice, according to a study published online Oct. 6 in Arthritis Care & Research.

FRIDAY, Oct. 12 (HealthDay News) -- Leflunomide is effective for the treatment of patients with psoriatic arthritis (PsA) in daily clinical practice, according to a study published online Oct. 6 in Arthritis Care & Research.

To assess the effectiveness and safety of leflunomide, Frank Behrens, M.D., from Johann Wolfgang Goethe-University in Frankfurt, Germany, and colleagues conducted a prospective, multinational 24-week observational study involving 514 adult patients (mean age, 50.7 years; mean disease duration, 6.1 years) with active PsA who began treatment with leflunomide. The Psoriatic Arthritis Response Criteria (PsARC) was used to assess response.

The researchers found that, in the primary effectiveness analysis, at 24 weeks, 380 of 440 patients (86.4 percent) achieved a PsARC response. Tender and swollen joint scores and counts improved significantly, as did patient and physician global assessments, fatigue, pain, skin disease, dactylitis, and nail lesions. The rate of treatment discontinuation was 12.3 percent. Adverse drug reactions occurred in 62 patients (12.1 percent), with three considered serious (two increased liver enzymes and one hypertensive crisis).

"On the basis of these data, we conclude that leflunomide is effective and has a favorable safety profile in the therapy of PsA in daily clinical practice," the authors write. "Its ability to alleviate joint, skin, and other disease manifestations; manageable safety profile; and relatively low price make leflunomide a valuable option for the treatment of PsA."

Several authors disclosed financial ties to sanofi-aventis, which funded the study.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Drug Class Linked to Worse Outcomes After Transplant Next: Cardiovascular IED Infections Have Distinct Features, Outcomes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.